Diagnostic Accuracy of Fecal Calprotectin Concentration in Evaluating Therapeutic Outcomes of Patients With Ulcerative Colitis

被引:20
作者
Stevens, Toer W. [1 ]
Gecse, Krisztina [1 ]
Turner, Jerrold R. [2 ]
de Hertogh, Gert [3 ]
Rubin, David T. [4 ]
D'Haens, Geert R. [1 ]
机构
[1] Univ Amsterdam, Amsterdam Univ Med Ctr, Dept Gastroenterol & Hepatol, Amsterdam, Netherlands
[2] Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Boston, MA USA
[3] Katholieke Univ Leuven, Dept Pathol, Leuven, Belgium
[4] Univ Chicago Med, Inflammatory Bowel Dis Ctr, Chicago, IL USA
关键词
Biomarker; Histology; Inflammatory Bowel Disease; Prognostic; C-REACTIVE PROTEIN; HISTOLOGICAL REMISSION; ENDOSCOPIC ACTIVITY; CLINICAL RELAPSE; DISEASE-ACTIVITY; INDUCTION; INDEX;
D O I
10.1016/j.cgh.2020.08.019
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND & AIMS: Histologic features of inflammation (histologic inflammation) are associated with clinical relapse in patients with ulcerative colitis (UC). Concentration of fecal calprotectin (FC) can be used to identify patients with mucosal inflammation. We aimed to assess the accuracy of FC measurements in identifying patients with histologic inflammation and to develop a model to predict outcomes of therapy. METHODS: We performed a post hoc analysis of data from a phase 4 trial of the efficacy of multimatrix mesalamine in patients with mild to moderate UC (the MOMENTUM trial). We obtained clinical, endoscopic, and histologic data from week 8 (n = 639) and week 52 (n = 373) of the trial. We used area under the receiver operating characteristic curves to determine the accuracy and optimal cut-off values of FC in identifying patients with different therapeutic outcomes (clinical remission, endoscopic healing, deep remission, or histologic remission) at week 8 and week 52. We performed multivariable logistic regression analyses to identify factors associated with these outcomes. RESULTS: Median FC concentrations were lower in patients who achieved outcomes of clinical remission, endoscopic healing, deep remission, or histologic remission vs patients who did not. FC concentrations identified patients with endoscopic healing and histologic remission with area under the receiver operating characteristic curve values of 0.77 and 0.76 at week 8, and 0.79 and 0.80 at week 52, respectively. The optimal FC cut-off concentrations for identification of patients with histologic remission were 75 mu g/g at week 8 and 99 mg/g at week 52. In the subpopulation with an endoscopy score of 0, median FC concentrations were lower in patients with histologic remission than in patients with microscopic inflammation at week 8 (30 vs 140 mu g/g; area under the receiver operating characteristic, 0.72) and week 52 (21.5 vs 134.5 mu g/g; area under the receiver operating characteristic, 0.71). At both time points, the optimal FC cutoff concentration was approximately 75 mu g/g. Our final prediction model for week 52 histologic remission comprised endoscopic score at week 8, FC concentration at week 8, and histologic activity at baseline and week 8. CONCLUSIONS: A post hoc analysis of data from a phase 4 trial found that, even in patients with complete endoscopic healing of UC, FC concentration can be used to discriminate patients with ongoing microscopic inflammation from patients with histologic remission. The optimal cut-off concentration of FC is between 75 and 100 mu g/g.
引用
收藏
页码:2333 / 2342
页数:10
相关论文
共 32 条
[1]   Prognostic Value of Serologic and Histologic Markers on Clinical Relapse in Ulcerative Colitis Patients With Mucosal Healing [J].
Bessissow, Talat ;
Lemmens, Bart ;
Ferrante, Marc ;
Bisschops, Raf ;
Van Steen, Kristel ;
Geboes, Karel ;
Van Assche, Gert ;
Vermeire, Severine ;
Rutgeerts, Paul ;
De Hertogh, Gert .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 (11) :1684-1692
[2]   Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD initiative [J].
Bossuyt, PM ;
Reitsma, JB ;
Bruns, DE ;
Gatsonis, CA ;
Glasziou, PP ;
Irwig, LM ;
Lijmer, JG ;
Moher, D ;
Rennie, D ;
de Vet, HCW .
ANNALS OF INTERNAL MEDICINE, 2003, 138 (01) :40-44
[3]   Systematic review: Histological remission in inflammatory bowel disease. Is 'complete' remission the new treatment paradigm? An IOIBD initiative [J].
Bryant, R. V. ;
Winer, S. ;
Travis, S. P. L. ;
Riddell, R. H. .
JOURNAL OF CROHNS & COLITIS, 2014, 8 (12) :1582-1597
[4]  
Collins GS, 2015, ANN INTERN MED, V162, P55, DOI [10.7326/M14-0697, 10.1016/j.jclinepi.2014.11.010, 10.1186/s12916-014-0241-z, 10.1038/bjc.2014.639, 10.7326/M14-0698, 10.1002/bjs.9736, 10.1136/bmj.g7594, 10.1016/j.eururo.2014.11.025]
[5]   Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease [J].
D'Haens, Geert ;
Ferrante, Marc ;
Vermeire, Severine ;
Baert, Filip ;
Noman, Maja ;
Moortgat, Liesbeth ;
Geens, Patricia ;
Iwens, Doreen ;
Aerden, Isolde ;
Van Assche, Gert ;
Van Olmen, Gust ;
Rutgeerts, Paul .
INFLAMMATORY BOWEL DISEASES, 2012, 18 (12) :2218-2224
[6]   Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naive patients with ulcerative colitis [J].
De Vos, M. ;
Dewit, O. ;
D'Haens, G. ;
Baert, F. ;
Fontaine, F. ;
Vermeire, S. ;
Franchimont, D. ;
Moreels, T. ;
Staessen, D. ;
Terriere, L. ;
Vander Cruyssen, B. ;
Louis, E. .
JOURNAL OF CROHNS & COLITIS, 2012, 6 (05) :557-562
[7]   The prognostic value of histology in ulcerative colitis in clinical remission with mesalazine [J].
Frieri, Giuseppe ;
Galletti, Brigida ;
Di Ruscio, Mirko ;
Tittoni, Rachele ;
Capannolo, Annalisa ;
Serva, Donatella ;
Latella, Giovanni ;
Sollima, Laura ;
Leocata, Pietro ;
Necozione, Stefano ;
Frieri, Rosamarie ;
Viscido, Angelo .
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2017, 10 (10) :749-759
[8]   A reproducible grading scale for histological assessment of inflammation in ulcerative colitis [J].
Geboes, K ;
Riddell, R ;
Öst, A ;
Jensfelt, B ;
Persson, T ;
Löfberg, R .
GUT, 2000, 47 (03) :404-409
[9]   Fibrosis in ulcerative colitis is directly linked to severity and chronicity of mucosal inflammation [J].
Gordon, I. O. ;
Agrawal, N. ;
Willis, E. ;
Goldblum, J. R. ;
Lopez, R. ;
Allende, D. ;
Liu, X. ;
Patil, D. Y. ;
Yerian, L. ;
El-Khider, F. ;
Fiocchi, C. ;
Rieder, F. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 47 (07) :922-939
[10]   Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management (Publication with Expression of Concern) [J].
Harbord, Marcus ;
Eliakim, Rami ;
Bettenworth, Dominik ;
Karmiris, Konstantinos ;
Katsanos, Konstantinos ;
Kopylov, Uri ;
Kucharzik, Torsten ;
Molnar, Tamas ;
Raine, Tim ;
Sebastian, Shaji ;
de Sousa, Helena Tavares ;
Dignass, Axel ;
Carbonnel, Franck .
JOURNAL OF CROHNS & COLITIS, 2017, 11 (07) :769-784